The
global mHealth market is being driven by
the increasing penetration of tablets and smartphones, and growing adoption of
connected healthcare devices and mHealth apps. Rising geriatric population
prone to chronic diseases, increasing focus on patent-centric healthcare, and growing
demand for remote patient monitoring are also helping in this regard. Generating
a revenue of $23.0 billion in 2017 as per a P&S Intelligence study, the
market is predicted to advance through the forecast period 2018–2023 at a CAGR
of 33.5%!
mHealth
refers to the collection of medical data and delivery of healthcare services
via mobile phones and tablets. On the basis of offering, the mHealth market can
be divided into mHealth apps, connected devices, and services. Among these, the
connected devices category led the market in 2017 with 57.2% share, due to a growing
demand for remote patient monitoring solutions. In places, where people’s
houses and healthcare centers are distant, these collect patients’ medical data
and send it to medical practitioners via the internet, thus allowing for real-time
disease management and improved patient outcomes.
Among
the several types of connected devices available are blood pressure monitors,
blood glucose monitors, multiparameter monitors, echocardiography (ECG) monitors,
sleep apnea monitors, pulse oximeters, and others. In 2017, blood pressure
monitors held the largest revenue share (28.7%) in the mHealth market owing to
an increased prevalence of chronic disease and the easy mobility of such
devices. While blood pressure monitors will still be the market leader during
the forecast period, blood glucose monitors will witness the highest CAGR
(31.9%) due to the increasing number of diabetes patients.
By
recording and sharing medical data, connected devices and mHealth apps also
lower the healthcare expenditure by minimizing hospital readmissions, clinic
revisits, medical tests, and other physical examinations. A study, conducted by
New York University, Harbin Institute of Technology and Carnegie Mellon
University between 2015 and 2016, showed that mHealth helped reduce the
glycated hemoglobin and blood glucose levels, hospital visits, and medical
expenses of type 2 diabetes patients.
No comments:
Post a Comment